{"id":11878,"date":"2011-08-09T20:14:57","date_gmt":"2011-08-10T00:14:57","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=11878"},"modified":"2011-08-09T23:08:34","modified_gmt":"2011-08-10T03:08:34","slug":"jj-to-settle","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/08\/09\/jj-to-settle\/","title":{"rendered":"J&#038;J to settle&#8230;"},"content":{"rendered":"<br \/>\n<blockquote>\n<div align=\"center\"><a href=\"http:\/\/www.nytimes.com\/2011\/08\/10\/business\/johnson-johnson-to-settle-charge-over-risperdal-marketing.html\" target=\"_blank\"><u><strong><font color=\"#200020\">Johnson &amp; Johnson to Settle Charge Over Drug&rsquo;s Marketing<\/font><\/strong><\/u><\/a><br \/>    <strong><font color=\"#200020\">New York Times<\/font><\/strong> <br \/>    By BLOOMBERG NEWS<br \/>    August 9, 2011<\/div>\n<p align=\"justify\"><sup>Johnson &amp; Johnson reached an agreement in principle to settle a  misdemeanor criminal charge related to the marketing of its  antipsychotic drug Risperdal, the company said in a regulatory filing on  Tuesday. Prosecutors have been investigating the company&rsquo;s Risperdal sales  practices since 2004, including accusations that it marketed the drug  for unapproved uses, Johnson &amp; Johnson said in <strong><a href=\"http:\/\/www.investor.jnj.com\/secfiling.cfm?filingID=950123-11-75098\" target=\"_blank\">its quarterly filing<\/a><\/strong>.<\/sup><\/p>\n<p align=\"justify\"><sup>&ldquo;Discussions have been ongoing in an effort to resolve criminal  penalties under the Food, Drug and Cosmetic Act related to the promotion  of Risperdal,&rdquo; Johnson &amp; Johnson said. &ldquo;Certain issues remain open  before a settlement can be finalized.&rdquo; The agreement in principle on the criminal charge is on a single  misdemeanor violation of the Food, Drug and Cosmetic Act, the company  said.<\/sup><\/p>\n<div align=\"justify\"><sup>The Justice Department and the United States attorney in Philadelphia  &ldquo;are continuing to pursue both criminal and civil actions,&rdquo; the company  said. Johnson &amp; Johnson said it had adjusted the accrued amount in the  second quarter of 2011 to cover the financial component of the proposed  criminal settlement, but did not disclose an amount for the reserve. The company said it was also in negotiations to settle civil  investigations related to the marketing of Risperdal and another drug,  Invega. It said it was not sure a settlement could be reached on those  claims.<\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\">While I&#8217;m not surprised that they&#8217;re settling, given their culpability, I am personally disappointed. I hope it doesn&#8217;t mean that the subpoenaed documents will be sealed. I want to see them &#8211; more accurately, I&#8217;d like for the world to see them. TMAP [and its spin-offs] was one of the most egregious and cynical PHARMA schemes in this whole psychopharmacology era, and it&#8217;s important that what J&amp;J [Janssen]&nbsp; did sees the light of day.&nbsp; I guess we&#8217;ll have to wait to see how it plays out but I&#8217;m hoping for a real TMAP trial in Texas in November&#8230;<\/div>\n<div align=\"right\">[see a more complete report at <a href=\"http:\/\/www.pharmalot.com\/2011\/08\/jj-to-settle-criminal-charge-over-risperdal-marketing-while-40-states-plan-lawsuit\/\" target=\"_blank\"><u><strong><font color=\"#006600\">Pharmalot<\/font><\/strong><\/u><\/a>]&#8230; <\/div>\n<div align=\"justify\">And in a paradoxically related posting on <strong>FiercePharma<\/strong>:<\/div>\n<blockquote>\n<div align=\"center\"><u><a target=\"_blank\" href=\"http:\/\/www.fiercepharma.com\/special-reports\/top-10-pharma-ceo-salaries-2010\"><strong><font color=\"#200020\">Top 10 Biopharma CEO salaries of 2010<\/font><\/strong><\/a><\/u><\/div>\n<p> <\/p>\n<div align=\"justify\">Welcome  to our annual look at the biggest CEO paychecks in the pharma industry.  <strong><font color=\"#200020\">Despite a year fraught with manufacturing issues and drug recalls,  Johnson &amp; Johnson CEO Bill Weldon takes the top spot, with $28.7  million in 2010 pay.<\/font><\/strong> And Novartis&#8217; Daniel Vasella grabs the number two  spot thanks to a lucrative golden handshake&#8230;       <\/div>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson to Settle Charge Over Drug&rsquo;s Marketing New York Times By BLOOMBERG NEWS August 9, 2011 Johnson &amp; Johnson reached an agreement in principle to settle a misdemeanor criminal charge related to the marketing of its antipsychotic drug Risperdal, the company said in a regulatory filing on Tuesday. Prosecutors have been investigating the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-11878","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=11878"}],"version-history":[{"count":11,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11878\/revisions"}],"predecessor-version":[{"id":11892,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11878\/revisions\/11892"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=11878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=11878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=11878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}